Skip to main content

South Korean pharma firms show interest in the Basel Area

| News

South Korean pharma firms show interest in the Basel Area

28.11.2022

Several South Korean firms from the life sciences industry, facilitated by the major Korean industry associations, have visited the Basel Area on fact-finding missions since October in connection with potentially establishing a presence in the region. An agreement with the largest industry association in South Korea and a delegation from Basel visiting Seoul laid the groundwork for these visits.

Delegation of Korean pharmaceutical companies with Basel Area representatives at the Main Campus of the Switzerland Innovation Park Basel Area

Several South Korean pharmaceutical companies have visited the Basel Area in recent months, some of them considering establishing a presence in the region as a base for their respective European subsidiaries. As the investment and innovation promotion agency, Basel Area Business & Innovation, has announced, a trio of South Korean firms recently travelled to Switzerland and the Basel Area on a fact-finding mission regarding the regional Life Sciences ecosystem. The trip was organized by the industry association KoreaBIO. The itinerary included visits to the Switzerland Innovation Park Basel Area at Novartis Campus and its Main Campus in Allschwil in the canton of Basel-Landschaft, where informative presentations were arranged covering the Basel Area and its ecosystem.

Macrogen, one of the world’s leading companies for precision medicine and biotechnology, based in Seoul, serves more than 18,000 customers from academic research and industry. The company has several overseas subsidiaries and branches in the United States, Europe, Japan, and Singapore. The biotech firm Stemon is developing digital induction of cell therapies using Entr technology. CEFO focuses on the pre-clinical stage of bone regeneration in the hip and spine.

Partnership agreement signed

This was preceded by a visit from two of South Korea’s largest pharmaceutical firms, Yuhan Corporation and Hanmi Pharmaceutical, at the end of October. “We are impressed by how strong the focus on science, technology and the development of new medicines is in Basel”, commented Lauren Young-Mi Lee, Head of R&D at Hanmi, in an article for the “Basler Zeitung” newspaper.

This significant interest in the Basel Area comes along with a city partnership agreement that was signed by Basel and Seoul on September 29. Moreover, Basel Area Business & Innovation and the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), South Korea’s largest association for the pharmaceutical industry, agreed terms on a partnership agreement in January 2022.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

Do you have a question? We'd like to hear from you.